Target Structure-Based Drug Discovery Group, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland 21702, USA.
J Chem Inf Model. 2010 Nov 22;50(11):2019-28. doi: 10.1021/ci1002894. Epub 2010 Oct 28.
We used synthetic peloruside A for the commercial preparation of [³H]peloruside A. The radiolabeled compound bound to preformed tubulin polymer in amounts stoichiometric with the polymer's tubulin content, with an apparent K(d) value of 0.35 μM. A less active peloruside A analogue, (11-R)-peloruside A and laulimalide acted as competitive inhibitors of the binding of the [³H]peloruside A, with apparent K(i) values of 9.3 and 0.25 μM, respectively. Paclitaxel, epothilone B, and discodermolide had essentially no ability to inhibit [³H]peloruside A binding, confirming that these compounds bind to a different site on tubulin polymer. We modeled both laulimalide and peloruside A into the binding site on β-tubulin that was identified by Huzil et al. (J. Mol. Biol. 2008, 378, 1016-1030), but our model provides a more reasonable structural basis for the protein-ligand interaction. There is a more complete desolvation of the peloruside A ligand and a greater array of favorable hydrophobic and electrostatic interactions exhibited by peloruside A at its β-tubulin binding site. In addition, the protein architecture in our peloruside A binding model was suitable for binding laulimalide. With the generation of both laulimalide and peloruside A binding models, it was possible to delineate the structural basis for the greater activity of laulimalide relative to peloruside A and to rationalize the known structure-activity relationship data for both compounds.
我们使用合成的 peloruside A 来商业化制备 [³H]peloruside A。放射性标记的化合物与预先形成的微管蛋白聚合物以与聚合物中微管蛋白含量成化学计量的方式结合,表观 K(d) 值为 0.35 μM。一种活性较低的 peloruside A 类似物,(11-R)-peloruside A 和 laulimalide 作为 [³H]peloruside A 结合的竞争性抑制剂,表观 K(i) 值分别为 9.3 和 0.25 μM。紫杉醇、埃坡霉素 B 和 discodermolide 基本上没有抑制 [³H]peloruside A 结合的能力,这证实了这些化合物结合到微管蛋白聚合物上的不同位点。我们将 laulimalide 和 peloruside A 分别模拟到 Huzil 等人确定的 β-微管蛋白结合位点(J. Mol. Biol. 2008, 378, 1016-1030),但我们的模型为蛋白-配体相互作用提供了更合理的结构基础。peloruside A 配体的去溶剂化更完全,并且在其 β-微管蛋白结合位点表现出更多有利的疏水和静电相互作用。此外,我们的 peloruside A 结合模型中的蛋白质结构适合结合 laulimalide。生成 laulimalide 和 peloruside A 结合模型后,就有可能阐明 laulimalide 相对于 peloruside A 具有更高活性的结构基础,并合理化这两种化合物的已知结构-活性关系数据。